Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
Chiara NovelliErika BorottoIvo BeverinaVeronica PunziDanilo RadrizzaniBruno BrandoPublished in: International journal of laboratory hematology (2021)
SARS-COV2 pneumonia patients in ICU have frequently heparin resistance. Anti-Xa seems a more reliable method to monitor heparin treatment than APTT in acute patients, also because the assay is insensitive to the increased levels of fibrinogen, FVIII, and LAC that are common during the COVID-19 inflammatory state.
Keyphrases
- sars cov
- intensive care unit
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- venous thromboembolism
- peritoneal dialysis
- prognostic factors
- respiratory syndrome coronavirus
- growth factor
- mechanical ventilation
- high throughput
- patient reported outcomes
- liver failure
- patient reported
- hepatitis b virus
- single cell
- combination therapy